• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biodesix Inc.

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email
    SC 13G 1 sc13g.htm FORM 13G BIODESIX


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.  4)*

     Biodesix, Inc.
    (Name of Issuer)
     
     Common stock, par value $0.001 per share
    (Title of Class of Securities)
     
    09075X108
    (CUSIP Number)
     
     
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    1
    NAMES OF REPORTING PERSONS
       
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     Telemark Asset Management, LLC
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     Delaware
       
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
       
     0
       
       
    6
    SHARED VOTING POWER
       
     8,282,490 shares
       
       
    7
    SOLE DISPOSITIVE POWER
       
     0
       
       
    8
    SHARED DISPOSITIVE POWER
       
     See Row 6 above
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     See Row 6 above
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     5.70%
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     IA;OO
       
       



    1
    NAMES OF REPORTING PERSONS
       
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     Telemark Fund, LP
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     Delaware
       
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
       
     0
       
       
    6
    SHARED VOTING POWER
       
      8,282,490 shares
       
       
    7
    SOLE DISPOSITIVE POWER
       
     0
       
       
    8
    SHARED DISPOSITIVE POWER
       
     See Row 6 above
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     See Row 6 above
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     5.70%
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     PN
       
       



    1
    NAMES OF REPORTING PERSONS
       
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     Colin S. McNay
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     USA
       
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
       
     0
       
       
    6
    SHARED VOTING POWER
       
     8,282,490 shares
       
       
    7
    SOLE DISPOSITIVE POWER
       
     0
       
       
    8
    SHARED DISPOSITIVE POWER
       
     See Row 6 above
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     See Row 6 above
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     5.70%
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     IN
       
       



    Item 1(a).
    Name of Issuer:

    Biodesix, Inc.

    Item 1(b).
    Address of Issuer's Principal Executive Offices:

    919 West Dillon Rd.
    Louisville, CO 80027

    Item 2(a).
    Name of Person Filing:

    This Schedule 13G is being jointly filed by Telemark Asset Management, LLC, Telemark Fund, LP and Colin McNay (collectively, the “Reporting Persons”) with respect to shares of Common Stock of Biodesix, Inc. Telemark Asset Management, LLC is the investment adviser of Telemark Fund, LP. Colin McNay is the President and sole owner of Telemark Asset Management, LLC.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement other than the securities actually owned by such person (if any).

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The address of the principal office of each Reporting Person is:

    One International Place, Suite 4620
    BOSTON MA 02110

    Item 2(c).
    Citizenship:

    Telemark Asset Management, LLC is a Delaware limited liability company and Telemark Fund, LP is a Delaware limited partnership.  Colin McNay is a U.S. citizen.

    Item 2(d).
    Title of Class of Securities:

    Common Stock, par value $0.001 per share

    Item 2(e).
    CUSIP Number:

    09075X108




    Item 3.
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a)
    ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e)
    ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f)
    ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g)
    ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h)
    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i)
    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j)
    ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k)
    ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .

    Item 4.
    Ownership.

    (a)
    Amount beneficially owned: 

    Each Reporting Person may be deemed to beneficially own 8,282,490 shares.

    (b)
    Percent of class:

    Each Reporting Person may be deemed to beneficially own what constitutes approximately 5.70% of the shares outstanding.

    (c)
    Number of shares as to which the person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 8,282,490 shares


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 8,282,490 shares





    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.

    Item 10.
    Certification.

    Each of the Reporting Person hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.





    SIGNATURE

    After reasonable inquiry and to the best of the signatory’s knowledge and belief, the signatory certifies that the information set forth in this statement is true, complete and correct.

    Dated: June 21, 2024

     
    TELEMARK ASSET MANAGEMENT, LLC
       
     
    By:
    /s/   Brian C. Miley
       
    Name: Brian C. Miley 
       
    Title: Chief Financial Officer 
       
       
     
    TELEMARK FUND, LP
       
     
    By: Telemark Asset Management, LLC,
    investment adviser
         
     
    By:
    /s/   Brian C. Miley
       
    Name: Brian C. Miley 
       
    Title: Chief Financial Officer 
       
       
         
     
    By:
    /s/ Colin McNay 
       
    Name: Colin McNay 
       
    Title: President and sole owner of
    Telemark Asset Management, LLC 






    EXHIBIT INDEX

    Exhibit
    Description of Exhibit
    99.1
    Joint Filing Agreement



    Get the next $BDSX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Strobeck Matthew

      4 - BIODESIX INC (0001439725) (Issuer)

      5/22/25 4:16:43 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Chairman Patience John

      4 - BIODESIX INC (0001439725) (Issuer)

      5/22/25 4:16:29 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Massarany Hany

      4 - BIODESIX INC (0001439725) (Issuer)

      5/22/25 4:16:13 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

      LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the Ame

      6/10/25 6:17:00 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

      LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center. The Ver

      5/22/25 5:03:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix to Participate in Upcoming Investor Conferences

      LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTLocation: Chicago, IL The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodes

      5/21/25 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    SEC Filings

    See more
    • SEC Form S-8 filed by Biodesix Inc.

      S-8 - BIODESIX INC (0001439725) (Filer)

      5/30/25 4:10:49 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Biodesix Inc.

      8-K - BIODESIX INC (0001439725) (Filer)

      5/21/25 4:43:05 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

      SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)

      5/20/25 4:11:48 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Financials

    Live finance-specific insights

    See more
    • Biodesix Announces First Quarter 2025 Results and Highlights

      Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. "Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline," said Sc

      5/13/25 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

      LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the

      4/29/25 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

      Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). "Biodesix concluded a strong 2024, advancing our key initiatives and delivering on our financial and operational goals," said Scott Hutton, Chief Executive Officer. "We exceeded our revenue targets, with total revenue re

      3/3/25 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

      Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

      12/16/22 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

      Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

      12/8/21 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

      SC 13G/A - BIODESIX INC (0001439725) (Subject)

      11/13/24 7:30:22 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Biodesix Inc.

      SC 13G - BIODESIX INC (0001439725) (Subject)

      6/24/24 12:16:38 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

      SC 13D/A - BIODESIX INC (0001439725) (Subject)

      5/23/24 7:10:37 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biodesix downgraded by William Blair

      William Blair downgraded Biodesix from Outperform to Mkt Perform

      5/14/25 8:54:25 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Biodesix

      Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

      9/16/24 8:45:16 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Craig Hallum initiated coverage on Biodesix with a new price target

      Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

      7/26/24 7:48:11 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schuler Jack W bought $1,316,624 worth of shares (4,723,239 units at $0.28) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      5/20/25 4:11:31 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Schuler Jack W bought $122,840 worth of shares (100,000 units at $1.23) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      11/22/24 12:30:34 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Kennedy Lawrence T. Jr bought $40,562 worth of shares (35,000 units at $1.16) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      11/22/24 12:30:13 PM ET
      $BDSX
      Medical Specialities
      Health Care